{"id":829872,"date":"2025-03-26T07:38:15","date_gmt":"2025-03-26T11:38:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-reports-positive-updated-data-from-sirexatamab-colorectal-cancer-study\/"},"modified":"2025-03-26T07:38:15","modified_gmt":"2025-03-26T11:38:15","slug":"leap-therapeutics-reports-positive-updated-data-from-sirexatamab-colorectal-cancer-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-reports-positive-updated-data-from-sirexatamab-colorectal-cancer-study\/","title":{"rendered":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS\u00a0
<\/i>
\n in second-line CRC patients with high DKK1<\/span> levels treated with sirexatamab plus bevacizumab and chemotherapy<\/i>\n <\/p>\n

\n Statistically significant 22% higher ORR and 2.6 month longer PFS
<\/i>
\n in patients who had not had prior\u00a0anti-VEGF therapy<\/i>\n <\/p>\n

\n Leap to host a conference call to present clinical data today, March 26, 2025<\/span>, at 8:00 a.m. ET<\/span><\/i>\n <\/p>\n

\n
\n CAMBRIDGE, Mass.<\/span>
\n <\/span>, March 26, 2025<\/span><\/span> \/PRNewswire\/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306<\/a>), a Phase 2, open-label, global study of sirexatamab (DKN-01), an anti-DKK1<\/span> monoclonal antibody, in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The updated analysis includes overall response rate (ORR), by both investigator-assessment (IA) and blinded independent central review (BICR), an additional two months of patient follow-up for progression-free survival (PFS) that demonstrates a favorable maturation of the data, and initial overall survival (OS) data. As of March 12, 2025<\/span>, 34 patients remain on study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.<\/p>\n

“The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1<\/span> or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue to strengthen over the coming months,” said Cynthia Sirard<\/span>, MD, Chief Medical Officer of Leap. “We believe that there is a compelling opportunity to move forward with a registrational study for sirexatamab to confirm these results and bring a new therapy to patients with CRC.”<\/p>\n

\n
\n DeFianCe Study Update<\/u>
\n <\/b>\n <\/p>\n